Clinical Trial Update: Regulation of Coagulation in Orthopedic Surgery to Prevent DVT and PE, a Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement [Phase 3]

View source ↗

Summary

Phase 3 randomized, double-blind study evaluating rivaroxaban (BAY 59-7939) for extended prevention of venous thromboembolism in patients undergoing elective to…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Deep Vein Thrombosis
• Pulmonary Embolism
• Venous Thromboembolism

Drugs mentioned

• Xarelto (rivaroxaban)

Snippet

Sponsor: Bayer | Conditions: Prevention, Venous Thromboembolism | Phase 3 | Status: COMPLETED